Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

In highly active MS, is skipping gadolinium an option?

Key clinical point: MRI detected most multiple sclerosis brain and spinal cord lesions, even without gadolinium contrast.

Major finding: T2/FLAIR sequences detected all but 7.9% of lesions visible on T1 sequences with gadolinium contrast.

Study details: A retrospective study of 84 patients with highly active disease at two multiple sclerosis centers in Italy.

Disclosures: Dr. Gentili reported receiving a travel grant from the ECTRIMS scientific program committee, and several coauthors reported relationships with multiple pharmaceutical companies. One coauthor received research funding from the Italian Multiple Sclerosis Society, the Italian Ministry of health, and the Italian Ministry of Education.

Citation:

Gentili L et al. ECTRIMS 2019, Abstract P901.